Posted by Michael Wonder on 10 Jul 2024
NICE recommends Ebglyss (lebrikizumab) for use in moderate to severe atopic dermatitis in the NHS England in eligible adolescents and adults
10 July 2024 - Following approval of the European Commission (October 2023) and the MHRA (December 2023), lebrikizumab will be available for prescription through the NHS in England and Wales.
Almirall announced today that NICE has recommended Ebglyss (lebrikizumab) for use in moderate to severe atopic dermatitis in the NHS England.
